281 related articles for article (PubMed ID: 19441904)
21. Sirt2 interacts with 14-3-3 beta/gamma and down-regulates the activity of p53.
Jin YH; Kim YJ; Kim DW; Baek KH; Kang BY; Yeo CY; Lee KY
Biochem Biophys Res Commun; 2008 Apr; 368(3):690-5. PubMed ID: 18249187
[TBL] [Abstract][Full Text] [Related]
22. Regulation of SIRT1 protein levels by nutrient availability.
Kanfi Y; Peshti V; Gozlan YM; Rathaus M; Gil R; Cohen HY
FEBS Lett; 2008 Jul; 582(16):2417-23. PubMed ID: 18544345
[TBL] [Abstract][Full Text] [Related]
23. SIRT1 and neuronal diseases.
Tang BL; Chua CE
Mol Aspects Med; 2008 Jun; 29(3):187-200. PubMed ID: 17397914
[TBL] [Abstract][Full Text] [Related]
24. Linking SIRT2 to Parkinson's disease.
Garske AL; Smith BC; Denu JM
ACS Chem Biol; 2007 Aug; 2(8):529-32. PubMed ID: 17708669
[TBL] [Abstract][Full Text] [Related]
25. SirT1 fails to affect p53-mediated biological functions.
Kamel C; Abrol M; Jardine K; He X; McBurney MW
Aging Cell; 2006 Feb; 5(1):81-8. PubMed ID: 16441846
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of human sirtuins by in situ generation of an acetylated lysine-ADP-ribose conjugate.
Asaba T; Suzuki T; Ueda R; Tsumoto H; Nakagawa H; Miyata N
J Am Chem Soc; 2009 May; 131(20):6989-96. PubMed ID: 19413317
[TBL] [Abstract][Full Text] [Related]
27. N(epsilon)-thioacetyl-lysine-containing tri-, tetra-, and pentapeptides as SIRT1 and SIRT2 inhibitors.
Kiviranta PH; Suuronen T; Wallén EA; Leppänen J; Tervonen J; Kyrylenko S; Salminen A; Poso A; Jarho EM
J Med Chem; 2009 Apr; 52(7):2153-6. PubMed ID: 19296597
[TBL] [Abstract][Full Text] [Related]
28. Strong expression of a longevity-related protein, SIRT1, in Bowen's disease.
Hida Y; Kubo Y; Murao K; Arase S
Arch Dermatol Res; 2007 May; 299(2):103-6. PubMed ID: 17180656
[TBL] [Abstract][Full Text] [Related]
29. SIRT2 down-regulation in HeLa can induce p53 accumulation via p38 MAPK activation-dependent p300 decrease, eventually leading to apoptosis.
Li Y; Matsumori H; Nakayama Y; Osaki M; Kojima H; Kurimasa A; Ito H; Mori S; Katoh M; Oshimura M; Inoue T
Genes Cells; 2011 Jan; 16(1):34-45. PubMed ID: 21059157
[TBL] [Abstract][Full Text] [Related]
30. Identification of a small molecule SIRT2 inhibitor with selective tumor cytotoxicity.
Zhang Y; Au Q; Zhang M; Barber JR; Ng SC; Zhang B
Biochem Biophys Res Commun; 2009 Sep; 386(4):729-33. PubMed ID: 19559674
[TBL] [Abstract][Full Text] [Related]
31. Identification of a cell-active non-peptide sirtuin inhibitor containing N-thioacetyl lysine.
Suzuki T; Asaba T; Imai E; Tsumoto H; Nakagawa H; Miyata N
Bioorg Med Chem Lett; 2009 Oct; 19(19):5670-2. PubMed ID: 19700324
[TBL] [Abstract][Full Text] [Related]
32. Sirtuin 1 (SIRT1): the misunderstood HDAC.
Stünkel W; Campbell RM
J Biomol Screen; 2011 Dec; 16(10):1153-69. PubMed ID: 22086720
[TBL] [Abstract][Full Text] [Related]
33. Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice.
Vakhrusheva O; Smolka C; Gajawada P; Kostin S; Boettger T; Kubin T; Braun T; Bober E
Circ Res; 2008 Mar; 102(6):703-10. PubMed ID: 18239138
[TBL] [Abstract][Full Text] [Related]
34. Small molecule regulation of Sir2 protein deacetylases.
Grubisha O; Smith BC; Denu JM
FEBS J; 2005 Sep; 272(18):4607-16. PubMed ID: 16156783
[TBL] [Abstract][Full Text] [Related]
35. Sirtuin activators.
Alcaín FJ; Villalba JM
Expert Opin Ther Pat; 2009 Apr; 19(4):403-14. PubMed ID: 19441923
[TBL] [Abstract][Full Text] [Related]
36. Aging and anti-aging: unexpected side effects of everyday medication through sirtuin1 modulation.
Engel N; Mahlknecht U
Int J Mol Med; 2008 Feb; 21(2):223-32. PubMed ID: 18204789
[TBL] [Abstract][Full Text] [Related]
37. FISH-mapping and genomic organization of the NAD-dependent histone deacetylase gene, Sirtuin 2 (Sirt2).
Voelter-Mahlknecht S; Ho AD; Mahlknecht U
Int J Oncol; 2005 Nov; 27(5):1187-96. PubMed ID: 16211212
[TBL] [Abstract][Full Text] [Related]
38. Neuronal protection by sirtuins in Alzheimer's disease.
Anekonda TS; Reddy PH
J Neurochem; 2006 Jan; 96(2):305-13. PubMed ID: 16219030
[TBL] [Abstract][Full Text] [Related]
39. Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition.
Trapp J; Jochum A; Meier R; Saunders L; Marshall B; Kunick C; Verdin E; Goekjian P; Sippl W; Jung M
J Med Chem; 2006 Dec; 49(25):7307-16. PubMed ID: 17149860
[TBL] [Abstract][Full Text] [Related]
40. Mechanism-based inhibition of Sir2 deacetylases by thioacetyl-lysine peptide.
Smith BC; Denu JM
Biochemistry; 2007 Dec; 46(50):14478-86. PubMed ID: 18027980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
